News brief­ing: Spring­Works, Jazz ex­change $35M and PTSD drug; Dr. Red­dy's says cy­ber­at­tack was ran­somware

Jazz Phar­ma­ceu­ti­cals is grab­bing an ex-Pfiz­er drug to beef up its mid-stage neu­ro­science port­fo­lio, pay­ing Spring­Works $35 mil­lion in cash for a new med for post-trau­mat­ic stress dis­or­der.

PF-04457845 is a FAAH in­hibitor that was orig­i­nal­ly test­ed for os­teoarthri­tis. But Spring­Works — and now Jazz — has po­ten­tial to ad­dress mul­ti­ple core symp­toms of PTSD, in­clud­ing fear ex­tinc­tion, anx­i­ety and dis­rupt­ed sleep ar­chi­tec­ture.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER